Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis

Scientific Reports
Yuya HorinouchiToshiaki Tamaki

Abstract

Renal tubulointerstitial injury, an inflammation-associated condition, is a major cause of chronic kidney disease (CKD). Levels of activated factor X (FXa), a blood coagulation factor, are increased in various inflammatory diseases. Therefore, we investigated the protective effects of an FXa inhibitor against renal tubulointerstitial injury using unilateral ureteral obstruction (UUO) mice (a renal tubulointerstitial fibrosis model) and the Food and Drug Administration Adverse Events Reporting System (FAERS) database. The renal expression levels of FX and the FXa receptors protease-activated receptor (PAR)-1 and PAR-2 were significantly higher in UUO mice than in sham-operated mice. UUO-induced tubulointerstitial fibrosis and extracellular matrix expression were suppressed in UUO mice treated with the FXa inhibitor edoxaban. Additionally, edoxaban attenuated UUO-induced macrophage infiltration and inflammatory molecule upregulation. In an analysis of the FAERS database, there were significantly fewer reports of tubulointerstitial nephritis for patients treated with FXa inhibitors than for patients not treated with inhibitors. These results suggest that FXa inhibitors exert protective effects against CKD by inhibiting tubulointer...Continue Reading

References

May 4, 2002·Nature Reviews. Molecular Cell Biology·James J TomasekRobert A Brown
Jul 23, 2003·Journal of the American Society of Nephrology : JASN·Giuseppe GrandalianoFrancesco P Schena
Sep 24, 2004·The New England Journal of Medicine·Alan S GoChi-yuan Hsu
Feb 15, 2005·Experimental Cell Research·Olivier P Blanc-BrudeRachel C Chambers
Nov 4, 2006·American Journal of Respiratory and Critical Care Medicine·Kazuhiko ShinagawaFrancis J Castellino
Sep 9, 2008·Trends in Molecular Medicine·Keren BorensztajnC Arnold Spek
Jan 9, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Allan J CollinsShu-Chen Chen
Jun 2, 2011·Biological & Pharmaceutical Bulletin·Ayaka SumiTakahiko Ono
Jun 26, 2013·International Journal of Medical Sciences·Toshiyuki SakaedaYasushi Okuno
Jul 2, 2014·Nature Reviews. Nephrology·Xiao-Ming MengHui Yao Lan
Sep 9, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Pengfei ZuoGenshan Ma
Oct 2, 2015·Biological & Pharmaceutical Bulletin·Natsumi UedaMitsuhiro Nakamura
Apr 7, 2016·Journal of Trace Elements in Medicine and Biology : Organ of the Society for Minerals and Trace Elements (GMS)·Yasumasa IkedaToshiaki Tamaki
Jun 11, 2016·Arteriosclerosis, Thrombosis, and Vascular Biology·Yuji OeNobuyuki Takahashi
Dec 28, 2016·Biochemical and Biophysical Research Communications·Sakiko HayashiNobuyuki Takahashi
Jan 13, 2017·International Journal of Clinical Pharmacology and Therapeutics·Mai FujimotoMitsutaka Takada
Nov 25, 2017·Journal of the American College of Cardiology·Xiaoxi YaoPeter A Noseworthy

❮ Previous
Next ❯

Citations

May 31, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yasumasa IkedaToshiaki Tamaki
Aug 28, 2019·International Journal of Molecular Sciences·Yuki NaritaKenichiro Kitamura
Nov 30, 2018·Journal of Cellular and Molecular Medicine·Maaike WaasdorpC Arnold Spek
Oct 21, 2020·Clinical Science·Sarah W Y LokSydney C W Tang
Dec 12, 2020·Kidney International·Hirofumi HamanoKoichiro Tsuchiya
Nov 19, 2021·Naunyn-Schmiedeberg's Archives of Pharmacology·Zhuang-Zhuang TangYao-Wu Liu

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assays
bronchoalveolar
lavage
PCR

Software Mentioned

ImageJ
MySQL

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.